Shenzhen XtalPi Technology Co., Ltd

Shenzhen XtalPi Technology Co., Ltd (XtalPi) is headquartered in International Biomedicine Industrial Park Phase 2. Its gross floor area is 12,000m², including 7,000m² for the comprehensive research laboratory. It has the drug synthesis laboratory, drug crystallization laboratory, analysis laboratory and automatic synthesis laboratory. This company was founded in the campus of Massachusetts Institute of Technology (MIT). By using quantum physics, quantum chemistry, AI and cloud computing technology, it provides intelligent drug R&D services to the global innovative pharmaceutical enterprises. It has branches operating in Beijing, Shanghai and Boston. It is a world-leading drug R&D unicorn enterprise whose innovation is driven by AI.

This company provides drug R&D services to over 70 pioneering pharmaceutical companies of the United States, Europe, China and Japan, and receives regular orders from some of the world's top 50 pharmaceutical enterprises including Pfizer (Pfizer Pharmaceuticals Ltd. of the United States, the No. 1 pharmaceutical company in the world), BI (Boehringer Ingelheim Pharmaceuticals Co., Ltd. of Germany, the No. 2 pharmaceutical company in Germany) and Eisai (Eisai Co., Ltd of Japan, the No. 2 pharmaceutical company in Japan). It has obtained USD 318.8 million (in excess of the expected amount) in Round C financing (a record high in terms of financing amount in the area of AI drug R&D). It has obtained about USD 400 million in Round D financing. It obtained over USD 700 million financing amount in one year, which is a record high in the industry. It strives to be the first profitable leading unicorn enterprise in the area of AI drug R&D in the world.